Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 340,058 |
|
|||||
| News | - | ||||||
| Day High | 0.505 | Low High |
|||||
| Day Low | 0.475 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BioVie Inc | BIVI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00645 | 1.32% | 0.49485 | 12:31:29 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.505 | 0.475 | 0.505 | 0.4884 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 915 | 340,058 | $ 0.4918912 | $ 167,272 | - | 0.445 - 8.69 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:31:29 | 200 | $ 0.49485 | USD |
BioVie Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 19.94M | 39.87M | - | 0 | -50.26M | -1.26 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
BioVie News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIVI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.4969 | 0.5499 | 0.4521 | 0.4924545 | 1,033,951 | -0.00205 | -0.41% |
| 1 Month | 0.562 | 0.6015 | 0.445 | 0.5096303 | 975,474 | -0.06715 | -11.95% |
| 3 Months | 0.8902 | 3.31 | 0.445 | 1.42 | 2,752,450 | -0.39535 | -44.41% |
| 6 Months | 3.11 | 5.82 | 0.445 | 1.72 | 1,698,456 | -2.62 | -84.09% |
| 1 Year | 8.15 | 8.69 | 0.445 | 2.07 | 957,330 | -7.66 | -93.93% |
| 3 Years | 13.05 | 23.86 | 0.445 | 3.85 | 505,168 | -12.56 | -96.21% |
| 5 Years | 10.50 | 46.0977 | 0.445 | 4.34 | 434,443 | -10.01 | -95.29% |
BioVie Description
| BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |
